Hepatitis

ACP, CDC Provides Best Practice Advice on Hepatitis B Management

ACP, CDC Provides Best Practice Advice on Hepatitis B Management

By

Screening, vaccination, and linkage to care will reduce the high costs associated with hepatitis B infection.

Effectiveness of Ledipasvir/Sofosbuvir for Acute HCV Infection in HIV

Effectiveness of Ledipasvir/Sofosbuvir for Acute HCV Infection in HIV

By

Study evaluated the optimal duration of ledipasvir/sofosbuvir for the treatment of acute hepatitis C virus (HCV) infection in HIV.

Preventing HCV Transmission: Utility of Needle/Syringe Programs

Preventing HCV Transmission: Utility of Needle/Syringe Programs

By

Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject drugs in Europe and North America, respectively.

Preventing HBV Reactivation During Immunosuppressive Treatment

Preventing HBV Reactivation During Immunosuppressive Treatment

By

Although it is commonly accepted that lamivudine prophylaxis should be started a few weeks before chemotherapy is administered, the best time for lamivudine discontinuation is still controversial.

Reduced Risk of Hepatic Steatosis in HIV/HCV Coinfection With Cannabis Use

Reduced Risk of Hepatic Steatosis in HIV/HCV Coinfection With Cannabis Use

By

Daily cannabis use remained significantly associated with lower odds of steatosis even after adjustment for BMI, which is known to be inversely correlated with cannabis use.

FDA Approves New Hepatitis B Vaccine for Adults

FDA Approves New Hepatitis B Vaccine for Adults

By

The FDA approves new hepatitis B virus vaccine for adults.

Increasing HCV Screening Using Electronic Health Record Prompts

Increasing HCV Screening Using Electronic Health Record Prompts

By

The rates of anti-HCV orders and tests were collected from 4 medical specialties within a 30 mile radius of University of Michigan, Ann Arbor campus.

A New Treatment Option for Patients With HCV and Severe Renal Impairment

A New Treatment Option for Patients With HCV and Severe Renal Impairment

By

Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, exhibit potent antiviral activity across all six major HCV genotypes.

Hepatitis C Transmission With Increased Risk Donor Organs Examined

Hepatitis C Transmission With Increased Risk Donor Organs Examined

By

Given the ongoing shortage of liver grafts, transplantation from HCV increased-risk donors to anti-HCV-negative recipients could potentially expand the donor pool.

Aspirin May Lower Risk of HBV-Related Hepatocellular Carcinoma

Aspirin May Lower Risk of HBV-Related Hepatocellular Carcinoma

By

Patients who take aspirin may significantly reduce their risk of hepatitis B-related hepatocellular carcinoma.

Using VA Models of Care for Reducing HCV Burden

Using VA Models of Care for Reducing HCV Burden

The US VA has developed models of care that can be used to reduce the overall burden of HCV infection.

Short-Duration Treatment Regimens for Chronic HCV: Latest Insights

Short-Duration Treatment Regimens for Chronic HCV: Latest Insights

By

The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved treatment adherence, and a reduced rate of side effects.

Challenges in Treating Genotype 3 Hepatitis C Virus

Challenges in Treating Genotype 3 Hepatitis C Virus

By

Data have shown patients with genotype 3 HCV have faster progression of fibrosis and higher rates of cirrhosis, severe steatosis, and hepatocellular carcinoma.

Antiviral Therapies Can Improve Fertility, Pregnancy Outcomes in HCV+ Women

Antiviral Therapies Can Improve Fertility, Pregnancy Outcomes in HCV+ Women

By

Researchers from the United States and Italy examined 3 cohorts of women to study rates of miscarriage and infertility in HCV, and how early antiviral treatment can affect them.

New Recommendations for Managing Hepatitis C Infection During Pregnancy

New Recommendations for Managing Hepatitis C Infection During Pregnancy

By

The recommendations will be published in the November issue of the American Journal of Obstetrics and Gynecology.

HCV Eradication With DAAs Associated With Reduced HCC Risk

HCV Eradication With DAAs Associated With Reduced HCC Risk

By

Treatment of hepatitis C virus with direct-acting antivirals was tied to a 71% reduction in the risk of liver cancer.

Elevated HBV Marker Increases Risk for Liver Cirrhosis

Elevated HBV Marker Increases Risk for Liver Cirrhosis

For hepatitis B virus (HBV) carriers, hepatitis B virus core-related antigen (HBcrAg) levels are associated with progression to cirrhosis.

HIV/HCV Co-Infections: Barriers to Effective Treatment

HIV/HCV Co-Infections: Barriers to Effective Treatment

By

Only a small percentage of people with HIV/HCV co-infection receive treatment for hepatitis C.

Efficacy of Ravidasvir Plus Sofosbuvir for Chronic Hepatitis C Genotype 4

Efficacy of Ravidasvir Plus Sofosbuvir for Chronic Hepatitis C Genotype 4

By

Researchers believe new once-daily dose of ravidasvir plus sofosbuvir is effective in treatment HCV genotype-4 and may be cost effective.

Direct-Acting Antivirals: The Gold Standard for HCV Recurrence Following Transplantation?

Direct-Acting Antivirals: The Gold Standard for HCV Recurrence Following Transplantation?

By

The majority of patients treated with second-generation direct-acting antiviral agents achieved sustained virologic response in 12 weeks.

Hepatitis C Treatment With Direct-Acting Antivirals Confers Survival Benefit

Hepatitis C Treatment With Direct-Acting Antivirals Confers Survival Benefit

By

Primary endpoints are to achieve sustained virologic response, improve survival rates, and lower complications of HCV.

Development Program for Hepatitis C Treatments Discontinued

Development Program for Hepatitis C Treatments Discontinued

By

Merck announced that the development programs for two hepatitis C virus infection treatments have been discontinued.

New HCV Guidelines Focus on Patient Population Treatments

New HCV Guidelines Focus on Patient Population Treatments

By

The American Association of the Study for Liver Diseases and the Infectious Diseases Society of America have added additional guidelines for the treatment of hepatitis C virus.

Law Implementation of HCV Testing Increases Screening Rates

Law Implementation of HCV Testing Increases Screening Rates

Mandating health care providers to offer hepatitis C virus screening can increase screening rates and linkage to care.

Treating Hepatocellular Carcinoma: A Fight Against the Odds

Treating Hepatocellular Carcinoma: A Fight Against the Odds

By

Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are diagnosed at an advanced stage of the disease.

Once-Daily Treatment Regime for Hepatitis C With Compensated Cirrhosis

Once-Daily Treatment Regime for Hepatitis C With Compensated Cirrhosis

By

Researchers assessed safety and tolerability throughout the 12 week study period and 24 weeks after completion of last dose of glecaprevir coformulated with pibrentasvir.

Vaccination Nearly Eliminates Hepatitis A Transmission in Alaska

Vaccination Nearly Eliminates Hepatitis A Transmission in Alaska

By

The effects of a statewide immunization effort on the transmission of hepatitis A was examined.

Effective HCV Treatment Decreases Chronic Kidney Disease Incidence

Effective HCV Treatment Decreases Chronic Kidney Disease Incidence

By

Minimally effective treatment of hepatitis C virus can prevent th edevelopment of chronic kidney disease.

Hepatitis B Reactivation Rate Linked to Inflammatory Arthritis Treatment

Hepatitis B Reactivation Rate Linked to Inflammatory Arthritis Treatment

By

Hepatitis B virus reactivation rates differ in patients with inflammatory arthritis.

Does Sustained Virologic Response Improve Glycemic Control in HCV?

Does Sustained Virologic Response Improve Glycemic Control in HCV?

By

Researchers compared HbA1c changes and use of antidiabetic medication in HCV with diabetes.

Sign Up for Free e-newsletters